SNDX Syndax Pharmaceuticals Inc
FY2025 10-K
Syndax Pharmaceuticals Inc (SNDX) filed its fiscal year 2025 10-K annual report with the SEC on Feb 26, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Commercial-stage biopharma focused on innovative cancer therapies with two FDA-approved drugs: Revuforj (menin inhibitor) and Niktimvo (CSF-1R antibody)
- • New FDA approval in Oct 2025 for Revuforj in relapsed/refractory AML with NPM1 mutation, expanding use beyond KMT2A translocation leukemia
Management Discussion & Analysis
- • Revenue $172.4M in 2025 vs $23.7M in 2024; net product revenue Revuforj $124.8M vs $7.7M, collaboration revenue Niktimvo $42.4M vs $0
- • Net loss $285.4M in 2025 vs $318.8M in 2024; operating loss $273.1M vs $339.7M; operating margin approx. -158.5% vs -143.3% (losss as % of revenue)
Risk Factors
- • Cybersecurity risk from IT system compromise with potential regulatory investigations and fines
- • Board audit committee oversees cybersecurity risk management with annual CFO reports on threats and mitigation
Financial SummaryXBRL
Revenue
$172M
Net Income
-$285M
Operating Margin
-158.4%
Net Margin
-165.6%
ROE
-441.6%
Total Assets
$530M
EPS (Diluted)
$-3.29
Operating Cash Flow
-$323M
Source: XBRL data from Syndax Pharmaceuticals Inc FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Syndax Pharmaceuticals Inc
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.